Biotechnology firm VERO Biotech has received expanded access emergency use from the US Food and Drug Administration (FDA) for its Genosyl DS to treat cardiopulmonary symptoms caused by Covid-19.
Previously, the FDA approved Genosyl, inhaled nitric oxide (iNO), for treating persistent pulmonary hypertension of the newborn (PPHN).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Genosyl DS is an iNO delivery system expected to aid during the short supply of hospital beds and ventilators.
